Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer
about
Surgery in the era of the 'omics revolutionBRCA1, a 'complex' protein involved in the maintenance of genomic stabilityAssociation of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data ApproachActivation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.Tumor homologous recombination deficiency assays: another step closer to clinical application?A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date.Molecular classification of non-invasive breast lesions for personalised therapy and chemopreventionDelivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer ProgramFrequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.Biology and Management of Patients With Triple-Negative Breast Cancer.Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells.DNA Damage and Repair Biomarkers of Immunotherapy Response.PICan: An integromics framework for dynamic cancer biomarker discovery.Combining large number of weak biomarkers based on AUC.Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.Danger signals: Chemotherapy enhancers?Rare cancers: the greatest inequality in cancer research and oncology treatment.Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
P2860
Q26852061-0943A96B-C191-495D-B5B3-348AA2D5905EQ26853262-42B046F9-01DA-4726-A08F-8332FA52551BQ30000323-BED7A0D7-C9E6-44CC-8D7A-19806DE96323Q33718199-F149B77C-5F37-46DD-96DF-98F9E27D4E94Q34520145-012FBFB8-7797-4AC2-AEF5-4A0970AFA27FQ34899498-211D3938-F67B-4B25-BC0D-C58DB1AEB696Q35664732-245AA333-28F4-4BEB-8AB5-3ED7262DCCADQ36141688-1160372E-4663-4B35-BAA7-5038C9EAF2F3Q36235523-7C5292E1-339F-41A0-9394-D5793B43D89BQ36685380-E18C412F-C835-4188-9D7F-49EF36C06735Q36893736-A10A6F32-79D8-42C6-AEE0-B84D65B57F93Q38744918-B37608C8-090D-4299-AC03-4B0E4CA5F29BQ38756892-A1BCEB65-F50D-4CC6-BE70-C9CABAA9AFD1Q38788928-52EAA5AC-0E38-409F-B744-B5C1712ABFB9Q38851459-D0B48B5D-F2D8-4028-96A1-6D5A719BB5E2Q38893074-D9938386-1A1F-4A3B-A178-E09E982FDFE2Q38973714-69CFB65A-4F54-4AE7-AEF4-B2B651C32B95Q39384263-2061FE36-D5F8-43DC-9C6C-813B8144F1DAQ40266748-2258CE0F-1272-492A-A494-9535935FFBFEQ40676243-E24A3388-C099-4D8A-9E45-252D0063226CQ42274807-A7A77266-4576-4A1C-B610-3E703C0728CDQ44857989-2332DB13-792E-4CCF-9AAA-2E5A5A6AF552Q47659090-6185E3CD-6246-4061-9ABE-EDC01BDFF4E0Q47684518-659E49B1-871D-4E30-A005-0FA751ABCE7BQ55055759-D88C3C12-5532-4122-AF0A-0934D84E64F0Q55710290-BABAC53E-A371-4F53-9A4B-4A4896C5B4B3
P2860
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification and validation ...... esponse assay in breast cancer
@en
Identification and validation ...... sponse assay in breast cancer.
@nl
type
label
Identification and validation ...... esponse assay in breast cancer
@en
Identification and validation ...... sponse assay in breast cancer.
@nl
prefLabel
Identification and validation ...... esponse assay in breast cancer
@en
Identification and validation ...... sponse assay in breast cancer.
@nl
P2093
P2860
P356
P1476
Identification and validation ...... esponse assay in breast cancer
@en
P2093
Colin R James
D Paul Harkin
David Boyle
Eamonn O'Brien
Fionnuala A McDyer
Gareth Irwin
Jacqueline James
Jennifer E Quinn
Jude M Mulligan
Katherine E Keating
P2860
P304
P356
10.1093/JNCI/DJT335
P407
P577
2014-01-01T00:00:00Z